GLP-1 clinical trials in Iowa: 7 recruiting now

7 GLP-1 clinical trials are recruiting at 8 sites in 4 cities across Iowa. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Iowa

1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

   Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

   A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

   Who can join. Adults 40 to 80, have type 2 diabetes.

   1 site in Iowa

   • University of Iowa, Iowa City. (319) 331-8773

2. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

   2 sites in Iowa

   • Iowa Digestive Disease Center, Clive. 833-602-2368
   • Iowa Diabetes and Endocrinology Research Center, West Des Moines. 833-602-2368

3. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

   1 site in Iowa

   • Iowa Diabetes and Endocrinology Research Center, West Des Moines. 833-602-2368

4. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

   A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

   1 site in Iowa

   • Iowa Diabetes and Endocrinology Research Center, West Des Moines

5. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

   Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

   A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

   Who can join. Adults 18+, have obesity, BMI 35+.

   1 site in Iowa

   • Iowa Diabetes Research, West Des Moines

6. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

   Phase 3. Run by AstraZeneca. Registry number NCT07662213.

   A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

   Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

   1 site in Iowa

   • Research Site, Ames

7. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

   Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

   A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

   Who can join. Adults 18 to 75, have obesity, BMI 27+.

   1 site in Iowa

   • Iowa Diabetes and Endocrinology Research Center, West Des Moines. 515-329-6800

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact